Fresenius SE & Co. KGaA (FRA:FRE)
Germany · Delayed Price · Currency is EUR | Market Cap | 23.45B |
| Revenue (ttm) | 22.13B |
| Net Income (ttm) | 422.00M |
| Shares Out | n/a |
| EPS (ttm) | 0.75 |
| PE Ratio | 55.58 |
| Forward PE | 12.09 |
| Dividend | 1.00 (2.41%) |
| Ex-Dividend Date | May 26, 2025 |
| Volume | 493,920 |
| Average Volume | 722,103 |
| Open | 42.01 |
| Previous Close | 41.44 |
| Day's Range | 41.28 - 42.21 |
| 52-Week Range | 30.36 - 44.40 |
| Beta | n/a |
| RSI | 47.78 |
| Earnings Date | Aug 6, 2025 |
About Smartsheet
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients; e... [Read more]
Financial Performance
Financial StatementsNews
Our U.S. investment has protected us - Fresenius CEO
Fresenius has raised its revenue outlook for the full-year, with the German healthcare group now expecting up to 7% organic growth. CEO Michael Sen tells CNBC's Silvia Amaro the company's local-to-loc...
Fresenius Lifts Full-Year Sales Outlook as Revamp Gains Momentum
Fresenius SE lifted its full-year sales outlook after a strong performance by the German health-care group’s hospitals and Kabi, its biopharma and MedTech unit.
EQS-PVR: Fresenius SE & Co. KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Fresenius SE & Co. KGaA Fresenius SE & Co. KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe...
Fresenius: Healthy Portfolio Add
Fresenius medical care outlines 2025 operating income growth targets amid strategic transformations
Fresenius SE & Co. KGaA 2025 Q1 - Results - Earnings Call Presentation
Fresenius SE & Co. KGaA (FSNUF) Q1 2025 Earnings Call Transcript
Fresenius SE & Co. KGaA reports Q1 results
Fresenius posts profit beat in first quarter, confirms outlook
German healthcare group Fresenius beat analysts' adjusted operating profit expectations for the first quarter on Wednesday, citing a strong performance at its drug making division Kabi.
Fresenius: Holding On For Longer-Term Growth Driven By Demand In Kidney Care Segment
EQS-AGM: Fresenius SE & Co. KGaA: Announcement of the Convening of the General Meeting in Frankfurt am Main on 23.05.2025 according to article 121 AktG (German Stock Companies Act) with the objective of Europe-wide distribution
EQS-News: Fresenius SE & Co. KGaA / Announcement of the Convening of the General Meeting Fresenius SE & Co. KGaA: Announcement of the Convening of the General Meeting in Frankfurt am Main on 23.05.202...
Pacira Settles Patent Dispute Over Exparel With Fresenius, Delays Pain Med' Generics Entry Until 2030, Stock Jumps
Pacira BioSciences, Inc . (NASDAQ: PCRX) on Monday settled its litigations with Fresenius Kabi USA , Jiangsu Hengrui Pharmaceuticals Co ., Ltd., and eVenus Pharmaceuticals Laboratories, Inc . related...
Pacira surges on patent settlement with Fresenius
EQS-PVR: Fresenius SE & Co. KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Fresenius SE & Co. KGaA Fresenius SE & Co. KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe...
EQS-DD: Fresenius SE & Co. KGaA: Robert Möller, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 01.04.2025 / 14:39 CET/CEST The issuer is solely responsi...
EQS-DD: Fresenius SE & Co. KGaA: Pierluigi Antonelli, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 01.04.2025 / 14:32 CET/CEST The issuer is solely responsi...
EQS-DD: Fresenius SE & Co. KGaA: Sara Hennicken, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 01.04.2025 / 14:20 CET/CEST The issuer is solely responsi...
EQS-DD: Fresenius SE & Co. KGaA: Michael Sen, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 01.04.2025 / 14:14 CET/CEST The issuer is solely responsi...
Fresenius gets FDA approval for biosimilars of Amgen's bone-condition drugs
Fresenius: Turnaround For Company, Stock Price
Fresenius SE's restructuring and dividend reinstatement signal strong growth. Read why FSNUF stock may not be a long-term buy despite short-term gains.
Health Care Roundup: Market Talk
Find insight on Bayer, Sandoz, Fresenius and more in the latest Market Talks covering Health Care.
EQS-Adhoc: Fresenius SE & Co. KGaA: Fresenius announces its intention to reduce its stake in Fresenius Medical Care AG from currently around 32.2% to no less than 25% plus one share
EQS-Ad-hoc: Fresenius SE & Co. KGaA / Key word(s): Investment Fresenius SE & Co. KGaA: Fresenius announces its intention to reduce its stake in Fresenius Medical Care AG from currently around 32.2% to...
Fresenius SE & Co KGaA (FSNUF) Full Year 2024 Earnings Call Highlights: Strong Growth and ...
Fresenius SE & Co KGaA (FSNUF) Full Year 2024 Earnings Call Highlights: Strong Growth and Strategic Advancements